Begin typing your search above and press return to search.
Hyderabad Company creates history
By: Tupaki Desk | 27 Aug 2013 2:31 PM GMTHyderabad-based pharma company Bharat Biotech launched World's first clinically proven typhoid vaccine and it has named it as Typbar - TCV. This vaccine could be used for infants above six-months and also for adults.
Bharat Biotech claimed its new vaccine would offer protection for more number of years than other existing ones which work for only two to three years. The company is yet to announce the price of the new vaccine which is about to hit the market in two weeks time.
However, the company's chairman Krishna M Ella said the new vaccine would be priced higher than the existing vaccine which costs Rs 180 per dose. He said that the company has researched for eight years to come up with World's first clinically proven typhoid conjugate vaccine. Around Rs 60 crore have been invested on this project and the company is expecting a business of Rs 100 crore now.
Typhoid is the most common disease in Asia which is transmitted through food or drink. As per World Heath Organization (WHO), about 90 percent of Typhoid deaths have been recorded in Asia.
Bharat Biotech claimed its new vaccine would offer protection for more number of years than other existing ones which work for only two to three years. The company is yet to announce the price of the new vaccine which is about to hit the market in two weeks time.
However, the company's chairman Krishna M Ella said the new vaccine would be priced higher than the existing vaccine which costs Rs 180 per dose. He said that the company has researched for eight years to come up with World's first clinically proven typhoid conjugate vaccine. Around Rs 60 crore have been invested on this project and the company is expecting a business of Rs 100 crore now.
Typhoid is the most common disease in Asia which is transmitted through food or drink. As per World Heath Organization (WHO), about 90 percent of Typhoid deaths have been recorded in Asia.
